Lack of elevated liver carcinogenicity of aminophenylnorharman in p53-deficient mice

Takeshi Iidaka, Tetsuya Tsukamoto, Yukari Totsuka, Akihiro Hirata, Hiroki Sakai, Norimitsu Shirai, Masami Yamamoto, Keiji Wakabayashi, Tokuma Yanai, Toshiaki Masegi, Lawrence A. Donehower, Masae Tatematsu

Research output: Contribution to journalArticlepeer-review

8 Citations (Scopus)


The hepatocarcinogenic potential of 9-(4′-aminophenyl)-9H-pyrido[3,4- b]indole (aminophenylnorharman, APNH) was investigated using male and female p53 deficient mice. Incidence of oval cell hyperplasia was 2/14 (14.3%), 14/23 (60.9%), and 2/10 (20%) in p53 nullizygous (-/-), heterozygous (+/-), and wild type (+/+) mice, respectively, exposed to 30 ppm APNH for 15 weeks, while hepatocellular anisonucleosis was observed only in APNH-treated p53 (-/-) mice. At 40 weeks, hepatocellular carcinomas had developed in 16/46 (34.8%) and 10/27 (37.0%) of female p53 (+/-) and (+/+) mice in contrast to only 1/45 (2.2%) and 2/12 (16.7%) in their male counterparts, respectively, without any detectable p53 gene mutations. Dose-dependent APNH-DNA adduct formation and transcriptional induction of CYP 1A1, but not CYP 1A2, was revealed with 7-day APNH treatment using female C57BL/6J mice. These results suggested hepatocarcinogenicity of APNH in mice could be linked to the liver microenvironment including hormonal milieu but independent of p53 expression and p53 gene mutations.

Original languageEnglish
Pages (from-to)149-159
Number of pages11
JournalCancer Letters
Issue number2
Publication statusPublished - 20-01-2005
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research


Dive into the research topics of 'Lack of elevated liver carcinogenicity of aminophenylnorharman in p53-deficient mice'. Together they form a unique fingerprint.

Cite this